EC Number |
Expression |
Reference |
---|
3.4.21.77 | down |
at a dose of 0.00001 mM 17-allylamine-17-demethoxygeldanamycin, PSA expression is reduced by 40%. 17-allylamine-17-demethoxygeldanamycin-treated LNCaP cells reveal about 25% inhibition of PSA secretion. Potency of AUY922 to reduce PSA expression at inhibitor concentrations lower than 0.000005 mM (non-toxic at these levels) is greater (8fold) than the potency of 17-allylamine-17-demethoxygeldanamycin. Hsp90 inhibitors target PSA secretion via the androgen receptor pathway |
708155 |
3.4.21.77 | down |
PSA expression is lower in malignant than in normal prostatic epithelium and it is further reduced in poorly differentiated tumors |
710554 |
3.4.21.77 | down |
PSA-specific monoclonal antibodies block proteolysis of extracellular matrix components and decrease invasion of PSA-producing LNCaP cells in Matrigel invasion assays |
707618 |
3.4.21.77 | down |
shRNA mediated knockdown of SNF2-related CBP activator protein results in decreased H2A.Z binding at the enhancer region of the PSA promoter and decreased expression of PSA in prostate cancer cells |
709244 |
3.4.21.77 | down |
treatment of LNCaP cells with 10 microg/ml soy isoflavones alone causes 40% inhibition of PSA secretion to the supernatant compared to control, whereas treatment of the cells with 20 micromol curcumin causes 20% inhibition. Combined treatment of curcumin and soy isoflavones enhances inhibition of PSA production and expression of androgen receptor in LNCaP cells: treatment with 10 microg/ml isoflavones combined with 20 micromol curcumin causes almost complete inhibition of PSA production. In a randomized, placebo-controlled clinical trial, a combined treatment of soy isoflavones and curcumin decreases serum PSA in those subjects whose baseline PSA is more than 10 ng/ml |
710462 |
3.4.21.77 | up |
inactive proenzyme is produced at high concentrations by epithelial cells of the prostate |
710554 |
3.4.21.77 | up |
LNCaP and 22RV1 xenograft tumors express PSA |
710463 |
3.4.21.77 | up |
SNF2-related CBP activator protein is a physiologically relevant mediator of PSA expression: it enhances the transcriptional activity of PSA and this activation is further enhanced in the presence of dihydrotestosterone. SNF2-related CBP activator protein activates hormone-dependent transcription of the androgen responsive, PSA-Luciferase reporter gene in prostate cells |
709244 |